Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically significant improvement in the frequency of cataplexy …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Self-efficacy involves one’s belief in their own ability to carry out tasks successfully. A psychological construct studied by psychologist Albert Bandura since the 1980s, it
Share this article The merger positioned Gilead to integrate CymaBay’s investigational lead product candidate, seladelpar, into its portfolio. Credit: Sundry Photography / Shutterstock.com. Gilead Sciences
Exposure to maternal COVID-19 was not associated with abnormal neurodevelopmental screening results through 24 months’ postpartum, according to a cohort study in JAMA Network Open.